Related Experiment Videos

Comparison in the same patient of aberrant conduction and bundle branch reentry after dofetilide, a new selective

H J Crijns1, J H Kingma, A T Gosselink

  • 1Department of Cardiology, University Hospital Groningen, The Netherlands.

Insights

Dofetilide can cause abnormal heart rhythms by affecting intraventricular conduction. This study reveals a mechanism involving bundle branch reentrant beats, highlighting a potential proarrhythmic risk with this drug.

Area of Science:

  • Electrophysiology
  • Cardiac Arrhythmias
  • Pharmacology

Background:

  • Dofetilide, a Class III antiarrhythmic agent, is used for atrial fibrillation.
  • Aberrant intraventricular conduction is a known potential side effect of Class III drugs.
  • Understanding the mechanisms of drug-induced arrhythmias is crucial for patient safety.

Observation:

  • This case study examined intraventricular conduction in an atrial fibrillation patient before and after dofetilide administration using endocardial recordings.
  • Dofetilide induced aberrant conduction during atrial fibrillation.
  • Aberrant conduction was reproducible with programmed atrial stimulation in sinus rhythm.

Findings:

  • Dofetilide provoked aberrant intraventricular conduction.
  • Bundle branch reentrant beats were observed during right ventricular stimulation.
  • This phenomenon was linked to critical retrograde conduction delays and differences in refractoriness between the right bundle branch and right ventricular myocardium.

Implications:

  • The findings suggest a specific proarrhythmic mechanism for dofetilide.
  • This mechanism involves bundle branch reentry, potentially exacerbated by drug-induced refractoriness changes.
  • Further investigation is warranted for dofetilide and similar Class III agents to mitigate proarrhythmic risks.

Related Concept Videos